Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | VNN1 | O95497 | 5/20 | 0.52 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.51 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.49 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27237606 | 0.84 | MAOA (0.47) | FFAR1FFAR4VNN1ERCC1ERCC4 | |
| SCHEMBL3461756 | 0.84 | ERCC1 (0.60) | FFAR1FFAR4VNN1ERCC1ERCC4 | |
| SCHEMBL5106820 | 0.79 | ERCC1 (0.44) | FFAR1FFAR4VNN1ERCC1ERCC4 | |
| SCHEMBL30525768 | 0.79 | ERCC1 (0.44) | FFAR1FFAR4VNN1ERCC1ERCC4 | |
| SCHEMBL2774523 | 0.78 | FFAR1 (0.52) | FFAR1FFAR4VNN1ERCC1ERCC4 | |
| SCHEMBL2007111 | 0.78 | CNR1 (0.62) | FFAR1FFAR4VNN1ERCC1ERCC4 | |
| SCHEMBL38654611 | 0.76 | ERCC1 (0.59) | VNN1ERCC1ERCC4LMNAMEP1A | |
| SCHEMBL8645386 | 0.76 | ERCC1 (0.59) | VNN1ERCC1ERCC4LMNAMEP1A | |
| SCHEMBL9365904 | 0.76 | MAOA (0.66) | VNN1ERCC1ERCC4MAOA | |
| SCHEMBL534926 | 0.76 | FFAR1 (0.53) | FFAR1FFAR4VNN1ERCC1ERCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160748-B2 | Indazolones as modulators of tnf signaling | ABBVIE INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2018-03-29 | — | — | US | disclosed |
| EP-3294726-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | AbbVie Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016168633-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | ABBVIE INC. | 2016-10-20 | — | — | US | disclosed |
| US-20080004256-A1 | Amidinophenylalanine Derivatives as Thrombin Inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2008-01-03 | — | — | US | disclosed |
| US-7285547-B2 | Amidinophenylalanine derivatives as thrombin inhibitors | LEK PHARMACEUTICALS D.D. (SI) | 2007-10-23 | — | — | US | disclosed |
| EP-1355894-B1 | AMIDINOPHENYLALANINE DERIVATIVES AS THROMBIN INHIBITORS | UNIV LJUBLJANI (SI) | 2005-03-16 | — | — | EP | disclosed |
| US-20040048851-A1 | Amidinophenylalanine derivatives as thrombin inhibitors | UNIVERZA V LJUBLJANA (SI) | 2004-03-11 | — | — | US | disclosed |
| EP-1355894-A1 | AMIDINOPHENYLALANINE DERIVATIVES AS THROMBIN INHIBITORS | UNIVERZA V LJUBLJANI, FAKULTETA ZA FARMACIJO (SI) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002051824-A1 | AMIDINOPHENYLALANINE DERIVATIVES AS THROMBIN INHIBITORS | UNIVERZA V LJUBLJANI (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048851-A1 | Amidinophenylalanine derivatives as thrombin inhibitors | TFPI, SERPINC1, F2 | FFAR1 3576/4885FFAR4 4164/4885VNN1 553/4885 |
| US-20080004256-A1 | Amidinophenylalanine Derivatives as Thrombin Inhibitors | TFPI, SERPINC1, F2 | FFAR1 3599/4885FFAR4 4148/4885VNN1 1453/4885 |
| US-20160304496-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | FFAR1 1504/4885FFAR4 1063/4885VNN1 4217/4885 |
| US-20180086737-A1 | INDAZOLONES AS MODULATORS OF TNF SIGNALING | TNF, CD40, TNFRSF1A | FFAR1 1504/4885FFAR4 1063/4885VNN1 4217/4885 |
| US-10160748-B2 | Indazolones as modulators of tnf signaling | TNF, CD40, TNFRSF1A | FFAR1 1504/4885FFAR4 1063/4885VNN1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.